Cargando…
Effects of switching from clopidogrel to prasugrel at the chronic phase after coronary stenting on antiplatelet action and vascular endothelial function: Switch-Pras study
Compared to clopidogrel, prasugrel has a lower incidence of ischemic events following percutaneous coronary intervention (PCI) because of an early reduction during the acute phase in P2Y12 reaction units (PRU). The objective of this study was to compare the antiplatelet effect and vascular endotheli...
Autores principales: | Masuyama, Taiki, Sakuma, Masashi, Waku, Ryutaro, Hirose, Suguru, Kitahara, Keijiro, Naganuma, Jin, Yazawa, Hiroko, Toyoda, Shigeru, Abe, Shichiro, Nakajima, Toshiaki, Inoue, Teruo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940291/ https://www.ncbi.nlm.nih.gov/pubmed/33113567 http://dx.doi.org/10.1007/s00380-020-01714-w |
Ejemplares similares
-
Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention
por: Koyabu, Yota, et al.
Publicado: (2019) -
Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018) -
Association of serum growth differentiation factor-15 with eGFR and hemoglobin in healthy older females
por: Yazawa, Hiroko, et al.
Publicado: (2020) -
Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
por: Kiebist, Jan, et al.
Publicado: (2021) -
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)